Compass Pathways' depression drug succeeds late-stage trial
23/06/2025 11:34
June 23 (Reuters) - Compass Pathways CMPS.O said on Monday its experimental psilocybin-based therapy helped significantly reduce symptoms of difficult-to-treat depression in a late-stage study. (Reporting by Mariam Sunny and Christy Santhosh in Bengaluru; Editing by Mrigank Dhaniwala) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on COMPASS Pathways
See all newsBrief: Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Trump's psychedelic drug order boosts investor interest with promise of faster reviews
UK's Compass Pathways Q1 operating income beats estimates as expenses fall
Health Rounds: Researchers gain new insight into how psychedelics affect the brain
U.S. STOCKS ON THE MOVE-Eli Lilly, Compass Pathways, Charter Communications